Waters Introduces the SARS-CoV-2 LC-MS Kit (RUO) toAdvance Clinical Research of Infectious Diseases
Waters Corporation (NYSE:WAT) today introduced a new RUO LC-MS test method to advance critical infectious disease research. Waters™ SARS-CoV-2 LC-MS Kit (RUO) uses an orthogonal analytical method that directly detects and quantifies SARS-CoV-2 Nucleocapsid (NCAP) peptides that initial studies have shown to yield highly accurate, quantitative results.
Source: businesswireindia.com